Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 12, 2015, Pages 2091-2099

  Klyuchnikov, Evgeny ^a   Bacher, Ulrike ^b   Kröger, Nicolaus M ^a   Hari, Parameswaran N ^c   Ahn, Kwang Woo ^c   Carreras, Jeanette ^c   Bachanova, Veronika ^d   Bashey, Asad ^e   Cohen, Jonathon B ^f   D'Souza, Anita ^c   Freytes, César O ^g   Gale, Robert Peter ^h   Ganguly, Siddhartha ⁱ   Hertzberg, Mark S ^j   Holmberg, Leona A ^k   Kharfan Dabaja, Mohamed A ^l   Klein, Andreas ^m   Ku, Grace H ⁿ   Laport, Ginna G ^o   Lazarus, Hillard M ^p   Miller, Alan M ^q   Mussetti, Alberto ^r,s   Olsson, Richard F ^t,u   Slavin, Shimon ^v   Usmani, Saad Z ^w   Vij, Ravi ^x   Wood, William A ^y   Maloney, David G ^k   Sureda, Anna M ^z,aa   Smith, Sonali M ^ab   Hamadani, Mehdi ^c   more..

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

^e Blood and Marrow Transplant Program at Northside Hospital   (Georgia)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^j PRINCE OF WALES HOSPITAL   (Australia)

^k USA   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m TUFTS MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^o STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^q BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^r NATIONAL CANCER INSTITUTE   (Italy)

^s UNIVERSITY OF MILAN   (Italy)

^t KAROLINSKA INSTITUTE   (Sweden)

^u UPPSALA UNIVERSITY   (Sweden)

^v International Center for Cell Therapy and Cancer Immunotherapy   (Israel)

^w LEVINE CANCER INSTITUTE   (United States)

^x WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^z HOSPITAL DURAN I REYNALS   (Spain)

^aa European Group for Blood and Marrow Transplantation   (Turkey)

^ab UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

Autologous hematopoietic cell transplantation; Grade 1 and 2 follicular lymphoma; Long time survival; Reduced intensity allogeneic hematopoietic cell transplantation

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; MYELOABLATIVE AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVOR; FEMALE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SECOND CANCER; TREATMENT OUTCOME; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CANCER GRADING; CLINICAL TRIAL; DISEASE COURSE; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LONGITUDINAL STUDY; LYMPHOMA, FOLLICULAR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SURVIVAL ANALYSIS; SURVIVOR; TRANSPLANTATION CONDITIONING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOPLASM GRADING; RECURRENCE; RITUXIMAB; SURVIVAL ANALYSIS; SURVIVORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84947494295     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.07.028     Document Type: Article

References (35)

1. Montoto S., Canals C., Rohatiner A.Z., et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukaemia 2007, 21:2324-2331.
2. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007, 25:2554-2559.
3. le Gouill S., de Guibert S., Planche L., et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica 2011, 96:1128-1135.
4. Passweg J.R., Baldomero H., Gratwohl A., et al. The EBMT activity survey: 1990-2010. Bone Marrow Transplant 2012, 47:906-923.
5. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21:3918-3927.
6. Sabloff M., Atkins H.L., Bence-Bruckler I., et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007, 13:956-964.
7. Ubieto A.J., García C.G., Yáñez L., et al. High dose therapy with autologous stem cell transplantation (HDT/ASCT) support in follicular lymphoma (FL): a very long follow-up analysis of 640 patients of GELTAMO Spanish Group suggests that FL might be cured, even in high-risk patients. ASH Annual Meetings Blood 2014, 124. [Abstract].
8. Sebban C., Brice P., Delarue R., et al. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA Study. J Clin Oncol 2008, 26:3614-3620.
9. Branson K., Chopra R., Kottaridis P.D., et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022-4031.
10. Hosing C., Saliba R.M., McLaughlin P., et al. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol 2003, 14:737-744.
11. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
12. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
13. Peniket A.J., Ruiz de Elvira M.C., Taghipour G., et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667-678.
14. Pinana J.L., Martino R., Gayoso J., et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010, 95:1176-1182.
15. Thomson K.J., Morris E.C., Milligan D., et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010, 28:3695-3700.
16. Shea T., Johnson J., Westervelt P., et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011, 17:1395-1403.
17. Tomblyn M.R., Ewell M., Bredeson C., et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 2011, 17:1051-1057.
18. Robinson S.P., Canals C., Luang J.J., et al. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. Bone Marrow Transplant 2013, 48:1409-1414.
19. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
20. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
21. Rezvani A.R., Maloney D.G. Rituximab resistance. Best Pract Res Clin Haematol 2011, 24:203-216.
22. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
23. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980, 69:204-217.
24. Zhang X., Loberiza F.R., Klein J.P., et al. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Programs Biomed 2007, 88:95-101.
25. Zhang X., Zhang M.J. SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models. Comput Methods Programs Biomed 2011, 101:87-93.
26. Evens A.M., Vanderplas A., la Casce A.S., et al. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 2013, 119:3662-3671.
27. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:2667-2674.
28. Sebban C., Mounier N., Brousse N., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006, 108:2540-2544.
29. Gyan E., Foussard C., Bertrand P., et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009, 113:995-1001.
30. Leisenring W., Friedman D.L., Flowers M.E., et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006, 24:1119-1126.
31. Rizzo J.D., Curtis R.E., Socie G., et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1175-1183.
32. Gopal A.K., Kahl B.S., de Vos S., et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014, 370:1008-1018.
33. Younes A., Thieblemont C., Morschhauser F., et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014, 15:1019-1026.
34. Casulo C., Byrtek M., Dawson K.L., et al. Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: an analysis from the national Lymphocare Study. ASH Annual Meetings Blood 2013, 122. [Abstract].
35. Mozessohn L., Cheung M.C., Crump M., et al. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis. Leuk Lymphoma 2014, 55:2502-2507.